These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 1293580)

  • 1. [Targeted immunotherapy against interleukin 2 receptors (IL-2R)--an attempt at synthesis].
    Sabliński T; Wasik MA; Tilney NL; Kupiec-Wegliński JW
    Postepy Hig Med Dosw; 1992; 46(3):275-85. PubMed ID: 1293580
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibition of allograft rejection and organ-specific autoimmune disease by anti-interleukin-2 receptor (IL-2R)-targeted immunotherapy. The action of anti-IL-2R monoclonal antibodies and synergistic effect of cyclosporin A.
    Diamantstein T; Mouzaki A; Osawa H; Volk HD; Hahn HJ; Kirkman RL; Strom TB; Tilney NL; Kupiec-Weglinski JW
    Dev Biol Stand; 1988; 69():177-84. PubMed ID: 3066671
    [No Abstract]   [Full Text] [Related]  

  • 3. Interleukin-2 receptor-targeted immune therapy.
    Diamantstein T; Hahn HJ
    Immunol Ser; 1993; 59():295-318. PubMed ID: 8461395
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunomodulation by interleukin-2 receptor targeted therapy.
    Gupta D; Naik S
    Natl Med J India; 1994; 7(2):67-70. PubMed ID: 8019399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy.
    Waldmann TA; Dubois S; Tagaya Y
    Immunity; 2001 Feb; 14(2):105-10. PubMed ID: 11239443
    [No Abstract]   [Full Text] [Related]  

  • 6. The multichain interleukin-2 receptor: a target for immunotherapy of patients receiving allografts.
    Waldmann TA; Goldman CK
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):45-53. PubMed ID: 2683757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of an immunocytokine, IL-2-183B2scFv, for targeted immunotherapy of ovarian cancer.
    Zhang X; Feng J; Ye X; Yao Y; Zhou P; Chen X
    Gynecol Oncol; 2006 Dec; 103(3):848-52. PubMed ID: 16806435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T cell targeted immunotherapy for autoimmune disease.
    Lee E; Sinha AA
    Autoimmunity; 2005 Dec; 38(8):577-96. PubMed ID: 16390811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of immunotherapy with anti-L3T4 monoclonal antibody on autoimmune cardiomyopathy: experiment with mice].
    Yuan J; Liao YH; Wang ZH; Cheng X; Zhang JH; Dong JH; Wang M
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(47):3346-9. PubMed ID: 16409842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Which immunological parameters are clinically essential to monitor IL-2 cancer immunotherapy?
    Lissoni P; Brivio F; Viviani S; Fumagalli L
    J Biol Regul Homeost Agents; 1999; 13(2):110-4. PubMed ID: 10503734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Interactions and biological mechanisms of action of molecular signal peptides. II. Interleukin 2 (IL-2)].
    Wustrow TP
    HNO; 1991 Sep; 39(9):323-31. PubMed ID: 1836210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-interleukin 2 receptor antibody suppresses murine diabetic insulitis and lupus nephritis.
    Kelley VE; Gaulton GN; Hattori M; Ikegami H; Eisenbarth G; Strom TB
    J Immunol; 1988 Jan; 140(1):59-61. PubMed ID: 3121742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-interleukin 2 fusion proteins: a new approach to cancer therapy.
    Reisfeld RA; Gillies SD
    J Clin Lab Anal; 1996; 10(3):160-6. PubMed ID: 8731505
    [No Abstract]   [Full Text] [Related]  

  • 14. Soluble and cell-associated IL-2 receptor (IL-2R) after local immunotherapy with recombinant interleukin-2 (rIL-2).
    Velotti F; Giuffrida A; Cippitelli M; Stoppacciaro A; Tubaro A; Ruco L; Santoni A
    Pharmacol Res; 1992 Sep; 26 Suppl 2():52-3. PubMed ID: 1409326
    [No Abstract]   [Full Text] [Related]  

  • 15. Manipulating IL-2 and IL-2R in autoimmune diseases and transplantation.
    Zhang M; Tang Q
    Immunotherapy; 2015; 7(12):1231-4. PubMed ID: 26601714
    [No Abstract]   [Full Text] [Related]  

  • 16. The therapeutic efficacy of an anti-IL-2 receptor monoclonal antibody correlates with an increase in serum soluble IL-2 receptor levels.
    Volk HD; Josimovic-Alasevic O; Gross M; Diamantstein T
    Clin Exp Immunol; 1989 Apr; 76(1):121-5. PubMed ID: 2786777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New therapeutic strategies for cell-mediated autoimmune diseases.
    Goldman M
    Acta Neurol Belg; 1994; 94(2):89-91. PubMed ID: 7913569
    [No Abstract]   [Full Text] [Related]  

  • 18. [Immunotherapy of malignant diseases].
    Dorval T; Michon J; Tartour E; Fridman WH
    Bull Cancer; 1995; 82 Suppl 2():127s-138s. PubMed ID: 7542946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The multichain interleukin 2 receptor. A target for immunotherapy in lymphoma, autoimmune disorders, and organ allografts [clinical reference].
    Waldmann TA
    JAMA; 1990 Jan; 263(2):272-4. PubMed ID: 2294293
    [No Abstract]   [Full Text] [Related]  

  • 20. [Interleukin 2 (IL-2) and its receptor (IL-2R) in healthy individuals and with various disease states].
    Mazur G; Frydecka I
    Acta Haematol Pol; 1993; 24(4):307-13. PubMed ID: 8303976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.